Kyowa Kirin CoKYKOF 82 ROC (Joel Greenblatt) % is 72.49% as of Dec. 2025, which is 85% above its 10-year median of 39.17. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $16.09 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 975 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 83.79% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Kyowa Kirin Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 72.49%.
The historical rank and industry rank for Kyowa Kirin Co's ROC (Joel Greenblatt) % or its related term are showing as below:
KYKOF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.63 Med: 39.17 Max: 55.82
Current: 47.27
During the past 13 years, Kyowa Kirin Co's highest ROC (Joel Greenblatt) % was 55.82%. The lowest was 17.63%. And the median was 39.17%.
KYKOF's ROC (Joel Greenblatt) % is ranked better than 83.79% of 975
companies
in the Drug Manufacturers industry
Industry Median: 11.44
vs KYKOF: 47.27
Kyowa Kirin Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 3.90% per year.
Kyowa Kirin Co (OTCPK:KYKOF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Kyowa Kirin Co ROC (Joel Greenblatt) % Related Terms
Kyowa Kirin Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KYKOF vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's ROC (Joel Greenblatt) % falls into.
Kyowa Kirin Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 72.49% mean?
Kyowa Kirin Co (KYKOF) has a ROC (Joel Greenblatt) % of 72.49% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Kyowa Kirin Co and its competitors. This is 85% above median its historical median of 39.17. Over the past decade, Kyowa Kirin Co's ROC (Joel Greenblatt) % has ranged from 17.63 to 55.82. According to the industry distribution chart, Kyowa Kirin Co ranks #158 out of 975 companies in the Drug Manufacturers industry, placing it in the top 16.2%.
Is Kyowa Kirin Co's ROC (Joel Greenblatt) % too high?
Kyowa Kirin Co's current ROC (Joel Greenblatt) % of 72.49% is 85% above median its 10-year median of 39.17. Over the past 10 years, this metric has ranged from a low of 17.63 to a high of 55.82. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.44. Kyowa Kirin Co's value of 72.49% is 533.7% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #158 out of 975 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #158 out of 975 companies for ROC (Joel Greenblatt) %. This places Kyowa Kirin Co in the top 16% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.44. Kyowa Kirin Co's value of 72.49% is 533.7% above this benchmark. Historically, Kyowa Kirin Co's own ROC (Joel Greenblatt) % has ranged from 17.63 to 55.82 over the past decade. While the company's 10-year median is 39.17 vs. the industry median of 11.44, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.44, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current ROC (Joel Greenblatt) % of 72.49% is 533.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current ROC (Joel Greenblatt) % is 72.49%, which is 85% above median its own 10-year median of 39.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.09, compared to a current price of $14.43 — trading 10.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 72.49%, which is 85% above median its 10-year median of 39.17 and 533.7% above the Drug Manufacturers industry median of 11.44. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current ROC (Joel Greenblatt) % is 72.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 10.3% below its estimated GF Value™ of $16.09.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for KYKOF:
ROC (Joel Greenblatt) %: 72.49% (85% above median its 10-year median of 39.17)
GF Value™: $16.09 vs. price of $14.43 (10.3% below fair value)
Industry Position: 533.7% above the Drug Manufacturers median (#158 of 975)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score
Get the complete analysis for KYKOF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
